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Skeletal muscle triglyceride levels are inversely related to insulin action 
Abstract 
In animal studies, increased amounts of triglyceride associated with skeletal muscle (mTG) correlate with 
reduced skeletal muscle and whole body insulin action. The aim of this study was to test this relationship 
in humans. Subjects were 38 nondiabetic male Pima Indians (mean age 28 ± 1 years). Insulin sensitivity 
at physiological (M) and supraphysiological (MZ) insulin levels was assessed by the euglycemic clamp. 
Lipid and carbohydrate oxidation were determined by indirect calorimetry before and during insulin 
administration. mTG was determined in vastus lateralis muscles obtained by percutaneous biopsy. 
Percentage of body fat (mean 29 ± 1%, range 14–44%) was measured by underwater weighing. In simple 
regressions, negative relationships were found between mTG (mean 5.4 ± 0.3 μmol/g, range 1.3–1.9 
μmol/g) and log10M (r = −0.53, P ≤ 0.001), MZ (r = −0.44, P = 0.006), and nonoxidative glucose disposal (r 
= −0.48 and −0.47 at physiological and supraphysiological insulin levels, respectively, both P = 0.005) but 
not glucose or lipid oxidation. mTG was not related to any measure of adiposity. In multiple regressions, 
measures of insulin resistance (log10M, MZ, log10[fasting insulin]) were significantly related to mTG 
independent of all measures of obesity (percentage of body fat, BMI, waist-to-thigh ratio). In turn, all 
measures of obesity were related to the insulin resistance measures independent of mTG. The obesity 
measures and mTG accounted for similar proportions of the variance in insulin resistance in these 
relationships. The results suggest that in this human population, as in animal models, skeletal muscle 
insulin sensitivity is strongly influenced by local supplies of triglycerides, as well as by remote depots and 
circulating lipids. The mechanism(s) underlying the relationship between mTG and insulin action on 
skeletal muscle glycogen synthesis may be central to an understanding of insulin resistance. 
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In animal studies, increased amounts of triglyceride associated with skeletal muscle (mTG) 
correlate with reduced skeletal muscle and whole body insulin action. The aim of this study 
was to test this relationship in humans. Subjects were 38 nondiabetic male Pima Indians (mean 
age 28 [+ or -] 1 years). Insulin sensitivity at physiological (M) and supraphysiological (MZ) 
insulin levels was assessed by the euglycemic clamp. Lipid and carbohydrate oxidation were 
determined by indirect calorimetry before and during insulin administration. mTG was 
determined in vastus lateralis muscles obtained by percutaneous biopsy. Percentage of body fat 
(mean 29 [+ or -] 1%, range 14-44%) was measured by underwater weighing. In simple 
regressions, negative relationships were found between mTG (mean 5.4 [+ or -] 0.3 
[micro]mol/g, range 1.3-1.9 [micro]mol/g) and [log.sub.10]M (r = -0.53, P [less than or equal 
to] 0.001), MZ (r = -0.44, P = 0.006), and nonoxidative glucose disposal (r = -0.48 and -0.47 at 
physiological and supraphysiological insulin levels, respectively, both P = 0.005) but not 
glucose or lipid oxidation, mTG was not related to any measure of adiposity. In multiple 
regressions, measures of insulin resistance ([log.sub.10]M, MZ, [log.sub.10][fasting insulin]) 
were significantly related to mTG independent of all measures of obesity (percentage of body 
fat, BMI, waist-to-thigh ratio). In turn, all measures of obesity were related to the insulin 
resistance measures independent of mTG. The obesity measures and mTG accounted for 
similar proportions of the variance in insulin resistance in these relationships. The results 
suggest that in this human population, as in animal models, skeletal muscle insulin sensitivity 
is strongly influenced by local supplies of triglycerides, as well as by remote depots and 
circulating lipids. The mechanism(s) underlying the relationship between mTG and insulin 
action on skeletal muscle glycogen synthesis may be central to an understanding of insulin 
resistance. Diabetes 46:983-988, 1997  
NIDDM, obesity, hypertension, dyslipidemias, and cardiovascular disease are all prevalent 
diseases that have been linked with impaired insulin action (insulin resistance) (1). Skeletal 
muscle has been identified as the primary site of insulin-stimulated glucose disposal at 
euglycemia (2,3) and, as such, is a major locus of insulin resistance. However, the mechanisms 
responsible for muscle insulin resistance remain unclear.  
Increased circulation lipid supply has been shown to impair glucose metabolism through 
effects on both glucose oxidation and storage (4-9). The corollary that decreasing lipid supply 
will increase glucose metabolism has also received strong experimental support (10,11). These 
studies have generally addressed circulating lipids; little information is available about the role 
of stored muscle lipids.  
Animal studies have shown that triglyceride associated with skeletal muscle (mTG) is an 
important source of lipid for energy within muscle (12,13). In addition, there is evidence to 
suggest that an intramuscular lipid pool may exist within human skeletal muscle as an 
immediate source of energy (14). In studies in the high-fat-fed rat, increases in storage 
triglyceride within single hindlimb muscles have been clearly associated with impairment in 
insulin-stimulated glucose metabolism in those same muscles (15). No such studies are 
available in humans. The aim of the present study was to examine the relationship between 
mTG and measures of insulin action in humans.  
RESEARCH DESIGN AND METHODS  
The sample cohort was 38 male Pima Indian volunteers of the Gila River Indian Community 
who were participating in a longitudinal study of the development of NIDDM (16). Subjects 
had a mean age of 28 [+ or -] 1 years, height 171.1 [+ or -] 0.8 cm, and weight 95.8 [+ or -] 3.1 
kg and were in good health as assessed by medical history and physical examination. All 
subjects gave informed consent, and the studies were al)proved by the ethics committees of the 
National Institutes of Health, the Indian Health Service, and the Gila River Indian Community.  
All subjects were admitted to the Phoenix Clinical Research Unit of the National Institutes of 
Health and stabilized for 2 days or more on a weight-maintenance diet (50% carbohydrate, 
30% fat, and 20% protein). Glucose tolerance was assessed after administration of a 75-g oral 
glucose load using World Health Organization criteria (17). Glucose tolerance was normal in 
all subjects. Body composition (percent body fat) was estimated by hydrodensitometry with 
simultaneous determination of lung residual volume (18,19).  
Euglycemic-hyperinsulinemic clamp. In vivo insulin mediated glucose disposal rate weeks 
measured by a two step euglycemic-hyperinsulinemic clamp (4). The clamp was performed by 
primed continuous low- and high-dose insulin infusions (290 and 2,900 pmol x [min.sup.-1] x 
[m.sup.-2], respectively), each of which was continued for 100 min while the plasma glucose 
was maintained at ~5.5 mmol/l. In vivo insulin action was determined during the period from 
60 to 100 min. During this time, plasma glucose uptake approached steady stale, but it is 
unlikely that a precise steady state was achieved. Nevertheless, in these studies, because 
comparisons are made between individuals and not the calculation of rates of glucose disposal 
or hepatic glucose production, this is not critical. Plasma glucose was measured by the glucose 
oxidase method using a glucose analyzer (Beckman Instruments, Fullerton, CA) and plasma 
insulin by radioimmunoassay using a radioassay analyzer (Concept 4, ICN, Horsham, PA).  
Indirect calorimetry. At 40 min before the initial insulin infusion and for the last 40 min during 
each of the insulin infusions, oxygen consumption and carbon dioxide production were 
determined by open-circuit indirect calorimetry (4). A transparent plastic hood was placed over 
the subject's head and secured around the neck with a soft collar. The subjects were supine and 
were asked to remain motionless and awake during the test. The flow rate was measured by 
using a pneumotachograph attached to a Fleisch flow transducer (Gould, Cleveland, OH). A 
constant fraction of the expired gases was withdrawn and analyzed for oxygen and carbon 
dioxide concentrations. Oxygen was measured by a zirconium cell analyzer and carbon dioxide 
by an infrared analyzer (Applied Electrochemistry, Sunnyvale, CA). The analyzers and 
flowmeter outputs were connected to a desktop computer (Hewlett Packard, Palo Alto, CA), 
which recorded continuous integrated calorimetric measurements over 5-min intervals. The 
basal and insulin-stimulated carbohydrate oxidation and lipid oxidation rates were calculated 
from indirect calorimetry data (20). Six subjects did not have indirect calorimetry determined.  
Muscle biopsy. At 2 days after the euglycemic-hyperinsulinemic clamp, a percutaneous biopsy 
of the vastus lateralis muscle was obtained. After a 12-h overnight fast, the skin and 
suprafascial tissue of the thigh were anesthetized with 8-10 ml of 1% lidocaine HCl (Astra 
Pharmaceutical Products, Westborough, MA), and the biopsy was performed with a Bergstrom 
needle (Depuy, Phoenix, AZ). The specimen was immediately frozen and stored in liquid 
nitrogen for later analysis.  
Skeletal muscle triglyceride analysis. Extraction and isolation of the lipid components of 
skeletal muscle have been described previously (21). in brief, muscle tissue was homogenized 
in 2:1 (vol/vol) chloroform:methanol and total lipids extracted. Nonpolar lipids were isolated 
by solid-phase extraction, and triglyceride content then was determined spectrophotometrically 
at 500 nm by using an enzymatic colorimetric test kit, Triglycerides GPO-PAP (Boehringer 
Mannheim, Sydney, Australia) and a Cary 3 spectrophotometer (Varian, Mulgrave, Australia). 
Samples were quantitated against a standard curve of Precimat glycerol (Boehringer 
Mannheim).  
Calculations. Total glucose disposal (at physiological [M] and supraphysiological [MZ] levels) 
was expressed as milligrams per minute per kilogram fat-free mass plus 17.7 based on the 
regression relationship observed in a large sample from the same population as the study group 
(20). Measures of glucose storage (at physiological [S] and supraphysiological [SZ] insulin 
concentrations) were calculated from the difference between the raw glucose disposal measures 
and carbohydrate oxidation measures and then expressed per kilogram of fat-free mass.  
Statistics. All statistical analyses were performed using the Statview SE+ graphics package 
(Abacus Concepts, Berkeley, CA). Relationships between variables were analyzed by simple 
correlation and by multiple and stepwise linear regressions. The significance of simple 
correlation coefficients was assessed using Fishers Z transformation. The significance of 
independent relationships in the multiple and stepwise regressions were assessed by a t test on 
the regression coefficients. Variables showing evidence of skewed distributions in larger 
published data sets in Pima Indians were log-transformed before analysis (M and fasting 
insulin). Stepwise regressions were performed in the forward direction with F for entry set to 4. 
Data are presented as means [+ or -] SE.  
 
RESULTS  
Members of the study group were young but overweight (Table 1), with mean body fat of 29 [+ 
or -] 1% (range 18 to 44%). Other subject characteristics, including measures of insulin action 
at M and MZ and basal and clamp carbohydrate/lipid oxidation values, are also listed in Table 
1.  
The mean value obtained for mTG in the skeletal muscles of the study group was 5.4 [+ or -] 
0.3 [micro]mol/g wet wt, with a range of 1.3-9.8 [micro]mol/g wet wt. A direct relationship 
was observed between mTG and the log fasting plasma insulin (LFPIns) values (r = 0.44, P < 
0.006). A negative relationship was found between the insulin action at the low dose of the 
euglycemic-hyperinsulinemic clamp and the triglyceride content (r = -0.53, P < 0.0006; Fig. 1). 
A similar relationship was found between skeletal mTG and insulin action at the 
supraphysiological insulin level (r = -0.44, P < 0.006).  
Measures of adiposity as determined by percent body fat, BMI, and waist-to-thigh ratio (W/T; 
as a measure of central adiposity) were significantly negatively related to insulin action 
(percent body fat and M: r = -0.50, P < 0.001; BMI and M: r = -0.49, P < 0.002; W/T and M: r 
= -0.49, P < 0.002). However, in contrast to the relationships observed between mTG and the 
three measures of insulin action, no significant relationships were found between mTG and any 
measure of adiposity (Table 1).  
Tables 2 and 3 show all possible permutations of the independent relationships between mTG, 
insulin action, and adiposity, mTG content was related to LFPIns, log M, and MZ independent 
of percent body fat, BMI, and W/T. In turn, all three measures of adiposity were related to all 
three measures of insulin action independent of mTG. However, adiposity and muscle 
triglyceride were not significantly related to each other in any manner.  
In a stepwise regression analysis of the various predictors of [log.sub.l0]M, only mTG (t = 
4.12, P = 0.0002) and W/T (t = 3.19, P = 0.003) were identified as independent correlates, with 
percent body fat and BMI not entering the regression. Together, mTG and W/T accounted for 
44% of the variance in [log.sub.10]M (29% of MZ).  
Both M (r = -0.51, P < 0.002) and MZ (r = -0.53, P < 0.001) were significantly negatively 
correlated with the respective clamp lipid oxidation rates, mTG was not related to any measure 
of lipid or carbohydrate oxidation either basally or during the low- or high-dose insulin 
infusions.  
mTG was significantly (P < 0.005) negatively related to S (r = -0.48) and SZ (r = -0.47), as 
shown in Table 1. Also, significant relationships were found between percent body fat, BMI, 
and W/T with S (r = -0.37, -0.39, and -0.36, respectively; all P < 0.05) but not with SZ (all P > 
0.05). However, the relationship between mTG and glucose storage was independent of all 
measures of adiposity.  
DISCUSSION  
An oversupply of lipid has been shown to lead to insulin resistance, whereas a reduction in 
lipid or reduced lipid oxidation and availability increases insulin action (11,23-25). Much of 
the experimental work has focused on circulating lipid supply. Infusions of triglyceride 
previously have been shown to reduce insulin-stimulated nonoxidative glucose disposal (9,26), 
whereas increased supply of free fatty acids is associated with reduced muscle glycogen 
accumulation (7,27). However, the present findings suggest that lipids other than those 
immediately available from the circulation may have major effects on insulin action. Even 
more surprising is that these postulated lipid effects are not only independent of adiposity but 
equally as powerful as the well-known effects of obesity on insulin action. Skeletal muscle 
contains energetically significant quantities of triglyceride (28), and studies in animals have 
shown that its content is negatively related to insulin action (15). The present study has 
provided strong support for a significant role of mTG in humans as a source of lipid to impair 
insulin-mediated glucose metabolism in muscle, in particular the nonoxidative component.  
Earlier work in animals (15) showed modulation of mTG by high-fat diets (59% of total 
calories as fat) with varying fatty acid profiles. Insulin action was directly assessed within 
individual tissues and triglyceride content determined within that same tissue. This current 
study assessed insulin action, via three different measures, at the whole body level, whereas 
triglyceride content was determined in a single muscle. Despite these methodological 
differences, a significant negative relationship between insulin action and skeletal muscle 
triglyceride content was again observed. This highlights the importance of skeletal muscle 
triglyceride content as a major variable in insulin-mediated glucose disposal in the body. These 
results alone cannot demonstrate either the existence or direction of causality. Equally, the 
Pima Indians are a particularly diabetes-prone group, and the present results require 
confirmation in other more insulin-sensitive populations. However, in conjunction with the 
animal studies where dietary (15) or pharmaceutical (25) manipulation of muscle triglyceride 
levels consistently alters insulin action in the predicted direction, they suggest that mTG may 
be a contributing cause of insulin resistance.  
 
 
Until now, circulating lipid has been considered the major lipid influence on glucose 
metabolism. However, clearly skeletal mTG represents another important factor. This point is 
emphasized by the lack of relationship between measures of whole body adiposity and mTG. 
In keeping with this, Groop et al. (30) have demonstrated that increasing insulin levels in obese 
individuals resulted in a similar decline in plasma free fatty acid oxidation to that in lean 
individuals. However, inhibition of total lipid oxidation (circulating and endogenous) was less 
sensitive to insulin in the obese, apparently due to a relative failure to suppress endogenous 
muscle lipolysis. Furthermore, insulin resistance has been linked with an indirect index of 
elevated lipid in muscle (reduced Hounsfield attenuation on computed tomography scans [31]). 
This latter study showed a strong negative correlation between glucose storage and this 
measure of increased muscle fat, findings consistent with the present results. These workers 
also found--again in line with the findings of this study--that measures of muscle fat and 
visceral obesity were independent predictors of insulin resistance. Moreover, stepwise 
regression revealed that an increased measure of muscle fat had the strongest predictive value 
for insulin resistance and together with visceral fat content accounted for 57% of the variance 
in glucose storage in the leg muscle that they analyzed. The parallels between these two sets of 
findings emphasize the dual but independent importance of mTG and visceral adiposity, 
possibly contributing through the influence on circulating lipids, in insulin-mediated glucose 
uptake. 
 
 
The amount of triglyceride in muscle found here is energetically significant. If fully oxidized 
for energy, it would provide ~50% of the energy potentially available from the glycogen levels 
reported in a similar group of Pima Indians (32). The only other study of insulin-resistant 
subjects found that triglyceride associated with rectus abdominis muscle biopsies obtained 
during surgery ranged from ~40 to 600 [micro]mol/g wet wt (5). These extraordinarily high 
values were most likely due to contamination from adipose depots. In keeping with the 
findings in this paper, other studies that have measured mTG yielded values of <50 
[micro]mol/g tissue (33-36). The skeletal muscle biopsies obtained in this study were from 
deep within the vastus lateralis and free of any visible signs of contamination from 
subcutaneous or other adipose depot stores. Thus, while the triglyceride was not localized to 
within the muscle fibers, early evidence suggests that it is (28); that is consistent with the 
excellent relation with insulin action independent of total body adiposity, which should relate 
more closely to intermuscle fat. However, it must be emphasized that we have not localized the 
lipid, and this is a matter of importance for further work.  
 
 
With regard to this latter point, trained athletes and animals show the same or higher levels of 
muscle triglycerides as sedentary controls (33-35,37) but have improved insulin action (38,39). 
This is unexpected in light of the relationship exposed in the current investigation, and the 
question is why do higher levels of triglyceride in trained individuals not lead to insulin 
resistance? The answer may lie in the distribution of that triglyceride. Endurance exercise 
increases both the mitochondrial volume and distribution in skeletal muscle (40). In addition, 
recent electron microscopy studies have revealed that in trained dogs, mitochondria appear 
virtually in direct contact with triglyceride droplets (37), in contrast with the lack of association 
with mitochondria in untrained animals. That may account both for the improved ability of 
trained individuals to mobilize fat for energy during moderate-intensity exercise and for the 
lack of a detrimental effect of such storage lipid on glucose metabolism. In contrast, in 
sedentary individuals the lipid may be located within neutral lipid domains of the plasma 
membrane itself (41,42), which may then affect second-messenger systems (43). Localization 
of lipid in one or more membranes may affect translocation of glucose transporters (44) or 
insulin receptor tyrosine kinase activity (45,46). Electron microscopy localization studies in 
sedentary and trained individuals would be instructive in this regard.  
Recently, we have shown in Pima Indians that the fatty acid profile of the major muscle 
membrane lipid (phospholipid) was closely linked to insulin action such that a higher 
proportion of saturated fats was associated with insulin resistance (47). In this subset of that 
study group, mTG was negatively related to the phospholipid unsaturation index (r = -0.323, P 
< 0.05; data not shown), such that the greater the proportion of unsaturated phospholipid fatty 
acids, the lower the stored skeletal muscle triglyceride. The mechanisms involved in this 
relationship are not proven, but it is consistent with the notion that saturated fats reduce the 
energy requirements of the cell due to reduced ion permeability (48,49), thereby tipping the 
balance away from lipid utilization for energy and toward storage.  
In summary, this study finds a significant negative relationship between muscle triglyceride 
content and nonoxidative glucose disposal in humans, concordant with and extending previous 
findings in rats. This relationship is independent of measures of total and central adiposity. 
Although the mechanisms responsible for this relationship are unclear, they may be central to 
an understanding of the link between lipid metabolism and insulin resistance.  
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LFPIns, log fasting plasma insulin; M and MZ, h)w-dose (physiological) and high-dose 
(supraphysiological) in vivo insulin-mediated glucose disposal rates, respectively; mTG, 
triglyceride associated with skeletal muscle; S and SZ, nonoxidative components of total 
glucose disposal at physiological and supraphysiological insulin concentrations, respectively; 
W/T, waist-to-thigh ratio.  
 
TABLE 1 
  
Mean values and ranges of anthropometric and metabolic variable and 
simple correlations with skeletal muscle associated triglyceride 
concentration (mTG) 
  
                                                    n 
  
BMI (kg/[m.sup.2])                                  38 
Percentage body fat                                 38 
Waist/thigh                                         38 
Fasting plasma glucose (mmol/1)                     38 
Fasting plasma insulin (pmol/1)                     38 
Total M ([mg x [min.sup.-1] x                       38 
  kg FF[M.sup.-1] + 17.7) 
Total MZ ([mg x [min.sup.-1] x                      38 
  kg FF[M.sup.-1] + 17.7) 
Basal oxidation (mg x                               32 
  [min.sup.-1] x kg FF[M.sup.-1]) 
  Carbohydrate 
  Lipid 
M oxidation (mg x [min.sup.-1] x                    32 
  kg FF[M.sup.-1]) 
  Carbohydrate 
  Lipid 
MZ oxidation (mg x [min.sup.-1] x                   32 
  kg FF[M.sup.-1]) 
  Carbohydrate 
  Lipid 
S (glucose storage component of M)                  32 
SZ (glucose storage                                 32 
  component of MZ) 
                                                  Value 
  
BMI (kg/[m.sup.2])                     32.7 [+ or -] 1.1 (19.0-52) 
Percentage body fat                      29 [+ or -] 1 (18-44) 
Waist/thigh                             1.6 [+ or -] 0.1 (1.3-2.2) 
Fasting plasma glucose (mmol/1)         5.0 [+ or -] 0.1 (4.1-6.0) 
Fasting plasma insulin (pmol/1)         220 [+ or -] 17 (85-677) 
Total M ([mg x [min.sup.-1] x           3.2 [+ or -] 0.2 (1.6-7.2) 
  kg FF[M.sup.-1] + 17.7) 
Total MZ ([mg x [min.sup.-1] x         8.8 [+ or -] 0.3 (3.9-13.4) 
  kg FF[M.sup.-1] + 17.7) 
Basal oxidation (mg x 
  [min.sup.-1] x kg FF[M.sup.-1]) 
  Carbohydrate                        1.64 [+ or -] 0.09 (0.70-3.10) 
  Lipid                               0.58 [+ or -] 0.04 (0.14-0.93) 
M oxidation (mg x [min.sup.-1] x 
  kg FF[M.sup.-1]) 
  Carbohydrate                        2.27 [+ or -] 0.09 (1.31-3.50) 
  Lipid                               0.32 [+ or -] 0.04 (-0.36-0.73) 
MZ oxidation (mg x [min.sup.-1] x 
  kg FF[M.sup.-1]) 
  Carbohydrate                        3.40 [+ or -] 0.10 (2.34-4.69) 
  Lipid                              -0.02 [+ or -] 0.04 (-0.47-0.38) 
S (glucose storage component of M)    0.93 [+ or -] 0.22 (-0.68-4.47) 
SZ (glucose storage 
  component of MZ)                    5.36 [+ or -] 0.31 (0.57-9.57) 
  
                                                    r 
  
BMI (kg/[m.sup.2])                                0.175 
Percentage body fat                               0.232 
Waist/thigh                                       0.026 
Fasting plasma glucose (mmol/1)                   0.100 
Fasting plasma insulin (pmol/1)                   0.435 
Total M ([mg x [min.sup.-1] x                    -0.531 
  kg FF[M.sup.-1] + 17.7) 
Total MZ ([mg x [min.sup.-1] x                   -0.438 
  kg FF[M.sup.-1] + 17.7) 
Basal oxidation (mg x 
  [min.sup.-1] x kg FF[M.sup.-1]) 
  Carbohydrate                                    0.035 
  Lipid                                           0.225 
M oxidation (mg x [min.sup.-1] x 
  kg FF[M.sup.-1]) 
  Carbohydrate                                    0.202 
  Lipid                                           0.265 
MZ oxidation (mg x [min.sup.-1] x 
  kg FF[M.sup.-1]) 
  Carbohydrate                                    0.192 
  Lipid                                           0.256 
S (glucose storage component of M)               -0.475 
SZ (glucose storage 
  component of MZ)                               -0.474 
  
                                                   p * 
  
BMI (kg/[m.sup.2])                                0.3 
Percentage body fat                               0.2 
Waist/thigh                                       0.9 
Fasting plasma glucose (mmol/1)                   0.6 
Fasting plasma insulin (pmol/1)                   0.006 
Total M ([mg x [min.sup.-1] x                     0.001 
  kg FF[M.sup.-1] + 17.7) 
Total MZ ([mg x [min.sup.-1] x                    0.006 
  kg FF[M.sup.-1] + 17.7) 
Basal oxidation (mg x 
  [min.sup.-1] x kg FF[M.sup.-1]) 
  Carbohydrate                                    0.8 
  Lipid                                           0.2 
M oxidation (mg x [min.sup.-1] x 
  kg FF[M.sup.-1]) 
  Carbohydrate                                    0.3 
  Lipid                                           0.1 
MZ oxidation (mg x [min.sup.-1] x 
  kg FF[M.sup.-1]) 
  Carbohydrate                                    0.3 
  Lipid                                           0.2 
S (glucose storage component of M)                0.005 
SZ (glucose storage 
  component of MZ)                                0.005 
  
Data are n or means [+ or -] SE (range), unless otherwise indicated. 
FFM, fat-free mass. r values were determined by simple regression 
against mTG. Regression against mTG was performed with the [log.sub.10] 
of fasting plasma insulin and total M values. * Significance level 
associated with r. 
  
TABLE 2 
  
Multiple regression results for the equation x2 
y = [a.sub.o] + [a.sub.l] [x.sub.l] + [a.sub.2] 
  
                             mTG=y 
  
Independent variables      t    P 
  
% fat                   0.037   <0.97 
LFPIns                  2.421   <0.02 
  
BMI                     0.254   <0.80 
LFPIns                  2.636   <0.01 
  
W/T                     1.318   <0.20 
LFPIns                  3.210   <0.003 
  
% fat                   0.242   <0.81 
LogM                    3.340   <0.002 
  
BMI                     0.671   <0.51 
LogM                    3.582   <0.001 
  
W/T                     1.546   <0.13 
Loges                   4.123   <0.0002 
  
% fat                   0.669   <0.51 
MZ                      2.544   <0.02 
  
BMI                     0.305   <0.76 
MZ                      2.660   <0.01 
  
W/T                     0.844   <0.40 
MZ                      3.023   <0.005 
  
t and P, significance of coefficients for [x.sub.l] and [x.sub.2] 
(i.e., independent effects as predictors); % fat, percent body fat. 
  
TABLE 3 
  
Multiple regression results for the equation y = [a.sub.o] + [a.sub.l] 
[x.sub.l] + [a.sub.2] [x.sub.2] 
  
Independent     LFPIns = y        LogM = y 
variables     t       P        t       P 
  
% fat         3.246   <0.003   2.985   <0.005 
mTG           2.421   <0.02    3.340   <0.002 
  
BMI           3.022   <0.005   3.167   <0.003 
mTG           2.636   <0.01    3.582   <0.001 
  
W/T           3.394   <0.002   3.194   <0.003 
mTG           3.210   <0.003   4.123   <0.0002 
  
Independent       MZ = y 
variables     t       P 
  
% fat         1.462   <0.15 
mTG           2.544   <0.016 
  
BMI           1.533   <0.13 
mTG           2.660   <0.01 
  
W/T           2.269   <0.03 
mTG           3.023   <0.005 
  
t and P, significance of coefficients for [x.sub.1] and [x.sub.2] 
(i.e., independent effects as predictors); % fat, percent body fat. 
 
